Form 4: Director Dani S. Zander Receives Medpace Stock Options

Medpace Holdings, Inc. director Dani S. Zander was granted 1,110 stock options as part of standard board compensation.

Summary

• Director Dani S. Zander received a grant of 1,110 stock options for Medpace Holdings, Inc. (MEDP) common stock.
• The options have an exercise price of $415.27 per share.
• The grant date for these options is May 15, 2026.
• The options are scheduled to expire on May 15, 2033.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine administrative filing regarding director compensation.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• None identified; this is a routine compensatory disclosure.

Risks

• Vesting is contingent upon continued service on the board of directors.

Future Outlook

The options vest on the earlier of the day before the next annual meeting or the first anniversary of the grant date, provided the director remains in service.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the clinical research organization (CRO) sector to ensure board retention and alignment with corporate performance.

Comparison to Industry Standards

• The grant of stock options to directors is consistent with standard corporate governance practices for mid-to-large cap companies in the healthcare services sector.

Corporate Governance

Stakeholder Impact

• Minimal impact on shareholders as this is a standard compensatory equity grant.

Next Steps

• Vesting of options on the earlier of the next annual meeting or May 15, 2027.

Key Dates

Keywords

Medpace, MEDP, Director Compensation, Stock Options, Insider Transaction, Form 4